{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:59:28Z","timestamp":1774400368243,"version":"3.50.1"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":54,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine Case Reports"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.rmcr.2026.102393","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T16:12:27Z","timestamp":1772122347000},"page":"102393","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Oritavancin as rescue therapy in severe methicillin-resistant Staphylococcus aureus pneumonia: A case report"],"prefix":"10.1016","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-1220-2518","authenticated-orcid":false,"given":"Francesco","family":"Virz\u00ec","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Giacopelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Tutone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandro","family":"Tomasello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.rmcr.2026.102393_bib1","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin. Infect. Dis."},{"issue":"5","key":"10.1016\/j.rmcr.2026.102393_bib2","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/cid\/cir895","article-title":"Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study","volume":"54","author":"Wunderink","year":"2012","journal-title":"Clin. Infect. Dis."},{"issue":"6","key":"10.1016\/j.rmcr.2026.102393_bib3","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00134-023-07033-8","article-title":"ERS\/ESICM\/ESCMID\/ALAT guidelines for the management of severe community-acquired pneumonia","volume":"49","author":"Martin-Loeches","year":"2023","journal-title":"Intensive Care Med."},{"issue":"1","key":"10.1016\/j.rmcr.2026.102393_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40121-016-0103-4","article-title":"Oritavancin: a new lipoglycopeptide antibiotic in the treatment of gram-positive infections","volume":"5","author":"Brade","year":"2016","journal-title":"Infect. Dis. Ther."},{"issue":"3","key":"10.1016\/j.rmcr.2026.102393_bib5","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1128\/AAC.00766-08","article-title":"Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro","volume":"53","author":"Belley","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.rmcr.2026.102393_bib6","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1128\/AAC.00176-15","article-title":"Population pharmacokinetic analysis for a single 1,200-milligram dose of oritavancin","volume":"59","author":"Rubino","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.rmcr.2026.102393_bib7","article-title":"Oritavancin for MRSA infections beyond skin: a review","volume":"58","author":"Smith","year":"2021","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"4","key":"10.1016\/j.rmcr.2026.102393_bib8","doi-asserted-by":"crossref","first-page":"959","DOI":"10.3390\/life13040959","article-title":"Role of oritavancin in the treatment of infective endocarditis, Catheter- or device-related infections, and bone and prosthetic joint infections","volume":"13","author":"Lupia","year":"2023","journal-title":"Life"},{"issue":"10","key":"10.1016\/j.rmcr.2026.102393_bib9","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.3390\/antibiotics12101498","article-title":"The clinical efficacy of multidose oritavancin: a systematic review","volume":"12","author":"Baiardi","year":"2023","journal-title":"Antibiotics (Basel)"},{"issue":"6","key":"10.1016\/j.rmcr.2026.102393_bib10","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02614-20","article-title":"New perspectives on antimicrobial agents: long-acting lipoglycopeptides","volume":"66","author":"Tran","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.rmcr.2026.102393_bib11","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jgar.2020.12.009","article-title":"Meta-analysis of vancomycin versus linezolid in pneumonia with proven methicillin-resistant Staphylococcus aureus","volume":"24","author":"Kato","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"10.1016\/j.rmcr.2026.102393_bib12","article-title":"Oritavancin for the treatment of infective endocarditis due to Gram-positive organism","author":"Terrero Salcedo","year":"2018","journal-title":"Ann Case Rep"},{"key":"10.1016\/j.rmcr.2026.102393_bib13","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12879-023-08725-8","article-title":"Oritavancin as sequential therapy for Gram-positive bloodstream infections","volume":"24","author":"Texidor","year":"2024","journal-title":"BMC Infect. Dis."},{"issue":"6","key":"10.1016\/j.rmcr.2026.102393_bib14","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1093\/jac\/dkp126","article-title":"Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium","volume":"63","author":"McKay","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"issue":"4","key":"10.1016\/j.rmcr.2026.102393_bib15","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.diagmicrobio.2014.09.003","article-title":"In vitro activity of oritavancin against Gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2013","volume":"80","author":"Karlowsky","year":"2014","journal-title":"Diagn. Microbiol. Infect. Dis."},{"issue":"5","key":"10.1016\/j.rmcr.2026.102393_bib16","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1574-6976.2003.tb00628.x","article-title":"Mechanism of action of oritavancin and related glycopeptide antibiotics","volume":"26","author":"Norris","year":"2003","journal-title":"FEMS Microbiol. Rev."}],"container-title":["Respiratory Medicine Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213007126000304?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213007126000304?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:19:55Z","timestamp":1774397995000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213007126000304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":16,"alternative-id":["S2213007126000304"],"URL":"https:\/\/doi.org\/10.1016\/j.rmcr.2026.102393","relation":{},"ISSN":["2213-0071"],"issn-type":[{"value":"2213-0071","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oritavancin as rescue therapy in severe methicillin-resistant Staphylococcus aureus pneumonia: A case report","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmcr.2026.102393","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102393"}}